EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Influence of body composition on the efficacy of nivolumab plus ipilimumab for metastatic clear cell renal cell carcinoma

Kabir Grewal, Maria Julia Moura Nascimento Santos, Pankaj Kumar Chauhan, Kai Yu, Nizar M Tannir, Sagar S Mukhida, Neha Venkatesh, Amishi Y Shah, Amado J Zurita, Andrew C Johns, Matthew T Campbell, Sangeeta Goswami und 6 weitere

Journal for ImmunoTherapy of Cancer · 2026-03 · 14 (3) · e014363

DOI: 10.1136/jitc-2025-014363 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 03.03.2026. Verfasst von Kabir Grewal und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Baylor College of Medicine, Houston, Texas, USA. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Ipilimumab, Body Composition. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Renal Medullary Carcinoma Research Foundation, V Foundation for Cancer Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immune checkpoint inhibitor therapy (ICI) with nivolumab+ipilimumab is a first-line (1L) standard for metastatic clear cell renal cell carcinoma (ccRCC), yet outcomes remain heterogeneous. Increasing evidence suggests that host factors influence the tumor microenvironment and response to ICI. Although higher body mass index (BMI) has been associated with improved outcomes in several malignancies, BMI is an imprecise surrogate for underlying adipose and muscle compartments. We evaluated the association between body composition and outcomes with 1L nivolumab+ipilimumab in metastatic ccRCC.

Methods

We retrospectively analyzed patients with mccRCC treated with 1L nivolumab+ipilimumab at MD Anderson Cancer Center between June 2015 and February 2024. Body composition was measured using an artificial intelligence segmentation tool at the L3 vertebra from pretreatment CT scans obtained within 45 days prior to starting therapy. Endpoints included real-world progression-free survival (PFS) and overall survival (OS). Multivariable Cox regression models, guided by directed acyclic graphs, evaluated associations between continuous body composition measures and outcomes, incorporating non-linear cubic splines. An exploratory analysis used single-cell RNA sequencing from 12 treatment-naïve patients with metastatic ccRCC, stratified by median Skeletal Muscle Mass Index (SMMi) and Subcutaneous Adipose Tissue Index (SATi) values.

Results

Among 309 patients (80.3% male, median age 61.9 years; 61.8% intermediate-risk and 28.5% poor-risk), increasing SMMi and SATi were independently associated with shorter PFS (HR 1.50, 95% CI 1.05 to 2.15 per 3-unit increase; and HR 1.39, 95% CI 1.01 to 1.90 per 10-unit increase). The associations of BMI, visceral adiposity, and skeletal muscle density with PFS were inconclusive. OS associations for all body-composition measures were likewise indeterminate. In the single-cell cohort, low SMMi was associated with numerically higher T-cell fractions (p=0.064), fewer myeloid cell proportions (p=0.10), and higher IDO1 expression.

Conclusions

Greater subcutaneous adiposity and skeletal muscle mass were associated with shorter PFS among patients with metastatic ccRCC treated with 1L nivolumab+ipilimumab. These findings support the concept that host body composition influences the heterogeneous clinical benefit observed with ICI in metastatic ccRCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsIpilimumabBody CompositionNivolumabAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMaleRetrospective StudiesMiddle AgedAged

Stichwörter der Autor:innen

Genitourinary CancerImmune Checkpoint InhibitorImmunotherapyKidney Cancer

Substanzen

IpilimumabNivolumab

Autor:innen und Institutionen

  • Department of Internal Medicine, Baylor College of Medicine, Houston, Texas, USA.
  • Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas, Houston, Texas, USA.
  • Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Förderung

  • NCI NIH HHS
  • Renal Medullary Carcinoma Research Foundation
  • V Foundation for Cancer Research
  • Philanthropic Support
  • Congressionally Directed Medical Research Programs
  • Kidney Cancer Association
  • Conquer Cancer Foundation
  • Prostate Cancer Foundation

Zitieren

APA

Grewal, K., Moura Nascimento Santos, M. J., Chauhan, P. K., Yu, K., Tannir, N. M., Mukhida, S. S., Venkatesh, N., Shah, A. Y., Zurita, A. J., Johns, A. C., Campbell, M. T., Goswami, S., Gao, J., Jonasch, E., McQuade, J. L., Alhalabi, O., Msaouel, P., & Hahn, A. W. (2026). Influence of body composition on the efficacy of nivolumab plus ipilimumab for metastatic clear cell renal cell carcinoma. Journal for ImmunoTherapy of Cancer, 14(3), e014363. https://doi.org/10.1136/jitc-2025-014363

Vancouver

Grewal K, Moura Nascimento Santos MJ, Chauhan PK, Yu K, Tannir NM, Mukhida SS, et al. Influence of body composition on the efficacy of nivolumab plus ipilimumab for metastatic clear cell renal cell carcinoma. Journal for ImmunoTherapy of Cancer. 2026;14(3):e014363. doi:10.1136/jitc-2025-014363

BibTeX
@article{Grewal2026,
  author = {Grewal, Kabir and Moura Nascimento Santos, Maria Julia and Chauhan, Pankaj Kumar and Yu, Kai and Tannir, Nizar M and Mukhida, Sagar S and Venkatesh, Neha and Shah, Amishi Y and Zurita, Amado J and Johns, Andrew C and Campbell, Matthew T and Goswami, Sangeeta and Gao, Jianjun and Jonasch, Eric and McQuade, Jennifer L and Alhalabi, Omar and Msaouel, Pavlos and Hahn, Andrew W},
  title = {Influence of body composition on the efficacy of nivolumab plus ipilimumab for metastatic clear cell renal cell carcinoma},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  volume = {14},
  number = {3},
  pages = {e014363},
  doi = {10.1136/jitc-2025-014363}
}
Kostenlos starten →